Skip to content
CA.gov logo in white
  • Grants Management System
  • CIRM Hub Portal
  • Contact
  • About
    • Our Mission
    • Our Impact
    • Our Governing Board
    • Strategic Goals
    • Our Team
    • Annual Reports
  • For Researchers
    • Funding Opportunities
    • Information for Applicants
    • Researcher Resources
    • Our Review Process
    • Manage Your Award
  • Our Programs
    • Grants Dashboard
    • Research and Development
    • Education and Training
    • Patient Access
  • Patient Resources
    • Stem Cell and Genetic Research
    • From Bench to Bedside
    • Community Outreach
    • Clinical Trials
    • Community Stories
  • News and Events
    • Press Releases
    • Public Meetings
    • Blog
    • Webinars and Workshops
  • About
    • Our Mission
    • Our Impact
    • Our Governing Board
    • Strategic Goals
    • Our Team
    • Annual Reports
  • For Researchers
    • Funding Opportunities
    • Information for Applicants
    • Researcher Resources
    • Our Review Process
    • Manage Your Award
  • Our Programs
    • Grants Dashboard
    • Research and Development
    • Education and Training
    • Patient Access
  • Patient Resources
    • Stem Cell and Genetic Research
    • From Bench to Bedside
    • Community Outreach
    • Clinical Trials
    • Community Stories
  • News and Events
    • Press Releases
    • Public Meetings
    • Blog
    • Webinars and Workshops

Treatment of Moderate to Severe Refractory Crohn’s Disease

  • Post author:
  • Post published:March 1, 2026
  • Post category:

Continue ReadingTreatment of Moderate to Severe Refractory Crohn’s Disease

SUPRAME-ACTengine® IMA203 vs. Investigator’s Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

  • Post author:
  • Post published:March 1, 2026
  • Post category:

Continue ReadingSUPRAME-ACTengine® IMA203 vs. Investigator’s Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

CAR-T Cells for HIV Infection

  • Post author:
  • Post published:March 1, 2026
  • Post category:

Continue ReadingCAR-T Cells for HIV Infection

A Study of NKX019, a CD19 CAR NK Cell Therapy, in Subjects With Systemic Lupus Erythematosus

  • Post author:
  • Post published:March 1, 2026
  • Post category:

Continue ReadingA Study of NKX019, a CD19 CAR NK Cell Therapy, in Subjects With Systemic Lupus Erythematosus

Safety, Tolerability and Efficacy Study of ARCT-032 in People With Cystic Fibrosis

  • Post author:
  • Post published:March 1, 2026
  • Post category:

Continue ReadingSafety, Tolerability and Efficacy Study of ARCT-032 in People With Cystic Fibrosis

A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer

  • Post author:
  • Post published:March 1, 2026
  • Post category:

Continue ReadingA2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer

A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.

  • Post author:
  • Post published:March 1, 2026
  • Post category:

Continue ReadingA Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.

A Feasibility Study Using CLINIMACS® for Alpha/Beta T-Cell Depletion in Stem Cell Transplant

  • Post author:
  • Post published:March 1, 2026
  • Post category:

Continue ReadingA Feasibility Study Using CLINIMACS® for Alpha/Beta T-Cell Depletion in Stem Cell Transplant

Transplantation of Clustered Regularly Interspaced Short Palindromic Repeats Modified Hematopoietic Progenitor Stem Cells (CRISPR_SCD001) in Patients with Severe Sickle Cell Disease

  • Post author:
  • Post published:March 1, 2026
  • Post category:

Continue ReadingTransplantation of Clustered Regularly Interspaced Short Palindromic Repeats Modified Hematopoietic Progenitor Stem Cells (CRISPR_SCD001) in Patients with Severe Sickle Cell Disease

IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)

  • Post author:
  • Post published:March 1, 2026
  • Post category:

Continue ReadingIMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)
  • Go to the previous page
  • 1
  • …
  • 28
  • 29
  • 30
  • 31
  • 32
  • Go to the next page
  • Careers
  • Administrative & Financials
  • Accessibility

Subscribe to Receive CIRM News

Get the latest CIRM news, information on upcoming meetings, and funding opportunities delivered to your inbox. 

Sign Up
Facebook-f X-twitter Instagram Linkedin Youtube
  • Privacy Policy
  • ©2025 California Institute for Regenerative Medicine
  • Media Guidelines
  • Contact Us